

Alaska Calendar Year 2026 Assessment

	Child				Adult			
	2025		2026		2025		2026	
Vaccine Cost Estimates								
Estimated Non-Flu Vaccine Cost Based on Current CDC Prices		\$ 11,111,706		\$ 10,261,774		\$ 2,806,534		\$ 2,929,626
Estimated Flu Vaccine Cost Based on Current CDC Prices		\$ 364,137		\$ 356,697		\$ 945,560		\$ 832,031
Estimated COVID-19 Vaccine Cost Based on Current CDC Prices		\$ 915,041		\$ 266,011		\$ 1,664,034		\$ 1,572,617
Total Estimated Vaccine Cost Based on Current CDC Prices		\$ 12,390,884		\$ 10,884,482		\$ 5,416,128		\$ 5,334,274
Provision for Vaccine Cost Increase	2.8%	\$ 343,563	2.8%	\$ 309,497	2.2%	\$ 118,285	2.6%	\$ 139,765
Vaccine Waste Allowance	4.5%	\$ 573,050	4.5%	\$ 503,729	4.5%	\$ 249,049	4.5%	\$ 246,332
Subtotal Estimated Vaccine Costs		\$ 13,307,497		\$ 11,697,708		\$ 5,783,462		\$ 5,720,371
Total Estimated Vaccine Costs		\$ 13,307,497		\$ 11,697,708		\$ 5,783,462		\$ 5,720,371
Total Administrative and Operating Costs		\$ 1,123,352		\$ 1,443,986		\$ 612,909		\$ 666,114
Total Reserves / Working Capital		\$ (3,080,779)		\$ (4,761,821)		\$ (1,861,287)		\$ (2,327,063)
Total Assessable Covered Lives Estimate		87,683		87,620		252,933		249,458
Assessment Calculation								
Total Assessment		\$ 11,350,069		\$ 8,379,872		\$ 4,535,084		\$ 4,059,422
Total Assessment Per Covered Life		\$ 129.44		\$ 95.64		\$ 17.93		\$ 16.27
Monthly Assessment Per Covered Life Calculated / % Change		\$ 10.79	-26.1%	\$ 7.97		\$ 1.49	-9.2%	\$ 1.36
Preliminary 2027 Projection								
Run Rate Monthly Assessment Per Covered Life		\$ 13.71		\$ 12.50		\$ 2.11		\$ 2.13
Excess Reserves Applied		\$ (2.96)		\$ (4.56)		\$ (0.62)		\$ (0.78)
Preliminary Assessment Projection	2.8%	\$ 11.13	2.8%	\$ 8.29	2.2%	\$ 1.53	2.6%	\$ 1.41
Preliminary Assessment Increase		3.21%		4.07%		2.73%		3.73%
Program Metrics								
Administrative and Operational Costs as % of Vaccine Costs		8.44%		12.34%		10.60%		11.64%
CDC Vaccine Costs as % Below Private Purchase Costs		-29.37%		-28.36%		-33.67%		-41.10%

Notes:

	Total	Allocated:	Child	Adult
Estimated cash balance at 12/31/2025	\$ 18,442,414		\$ 12,387,845	\$ 6,054,568
Less: Cash reserves needed (3 months vaccines)	(4,167,004)		(2,798,495)	(1,368,510)
Estimated excess cash	14,275,409		9,589,350	4,686,059
50% release to 2026 Assessment Rate	7,137,705		4,794,675	2,343,029
0.25% estimate for bad debt	(48,820)		(32,854)	(15,966)
Total Reserves/Working Capital released in 2026	\$ 7,088,884		\$ 4,761,821	\$ 2,327,063

Alaska Calendar Year 2026 Assessment

Change in Assessment (from 2025 to 2026)

	Child			Adult		
	Cost	PMPM	% Change	Cost	PMPM	% Change
2025	\$11,350,069	\$ 10.79		\$4,535,084	\$ 1.49	
Change In:						
Contribution Enrollees		\$ 0.00	0.0%		\$ 0.02	1.1%
Estimated Vaccine Cost	\$ (1,506,402)	\$ (1.43)	-13.3%	\$ (81,855)	\$ (0.03)	-2.0%
Provision For Vaccine Cost Increase	\$ (34,066)	\$ (0.03)	-0.3%	\$ 21,480	\$ 0.01	0.7%
Vaccine Waste Allowance	\$ (69,321)	\$ (0.07)	-0.6%	\$ (2,717)	\$ -	0.0%
Administrative Costs	\$ 317,883	\$ 0.30	2.8%	\$ 53,297	\$ 0.02	1.3%
Operational Costs	\$ 2,751	\$ -	0.0%	\$ (91)	\$ -	0.0%
Reserve/Working Capital	\$ (1,681,042)	\$ (1.60)	-14.8%	\$ (465,776)	\$ (0.16)	-10.7%
2026	\$8,379,872	\$ 7.97	-26.1%	\$4,059,422	\$ 1.36	-9.2%

Alaska Vaccine Assessment Program

	2026 Calendar Year			2026 Calendar Year			2025 Calendar Year		
	WITH Medicare Fees			WITHOUT Medicare Fees			2025 Calendar Year		
	Child	Adult	Total	Child	Adult	Total	Child	Adult	Total
A CDC Survey Market Comparison Costs (Actual doses per brand x CDC market survey)	\$ 16,328,934	\$ 9,714,416	\$ 26,043,350	\$ 16,328,934	\$ 9,714,416	\$ 26,043,350	\$ 18,840,785	\$ 8,715,249	\$ 27,556,035
Cost of Vaccine Replenishments	\$ 11,697,708	\$ 5,720,371	\$ 17,418,079	\$ 11,697,708	\$ 5,720,371	\$ 17,418,079	\$ 13,307,497	\$ 5,783,462	\$ 19,090,959
Operating and Administrative Expenses	\$ 1,341,337	\$ 618,763	\$ 1,960,100	\$ 1,341,337	\$ 618,763	\$ 1,960,100	\$ 1,123,352	\$ 612,909	\$ 1,736,260
Medicare Fees, Phase 2	\$ -	\$ 150,000	\$ 150,000	\$ -	\$ -	\$ -			
B Total Program Costs	\$ 13,039,045	\$ 6,489,134	\$ 19,528,179	\$ 13,039,045	\$ 6,339,134	\$ 19,378,179	\$ 14,430,848	\$ 6,396,371	\$ 20,827,219
C Program Savings (A – B = C)	\$ 3,289,889	\$ 3,225,283	\$ 6,515,172	\$ 3,289,889	\$ 3,375,283	\$ 6,665,172	\$ 4,409,937	\$ 2,318,879	\$ 6,728,816
D Overall Program Savings Percentage (C / A = D)	20.1%	33.2%	25.0%	20.1%	34.7%	25.6%	23.4%	26.6%	24.4%
E Covered Lives	87,620	249,458	337,078	87,620	249,458	337,078	87,683	252,933	340,616
F Savings per covered life per year (C / E = F)	\$ 37.55	\$ 12.93	\$ 19.33	\$ 37.55	\$ 13.53	\$ 19.77	\$ 50.29	\$ 9.17	\$ 19.75

Alaska Calendar Year 2026 Assessment

CDC vaccine costs are 33% lower than private purchase costs (overall, child & adult).

Top 10 Vaccines - Child

Vaccine	Brandname/ Tradename	NDC	Dose Quantity	CDC Cost/ Dose	Projected Vaccine Cost	% of Total	Private Sector Cost/ Dose	Projected Private Cost	\$ Savings Per Dose
Pneumococcal	Pprevnar 20TM	00005-2000-10	10,370	\$ 192.46	\$ 2,144,226	18%	\$ 274.60	\$ 3,059,360	\$ 88.25
HPV – Human Papillomavirus 9-valent F	Gardasil®9	00006-4121-02	7,620	\$ 257.07	\$ 2,104,550	18%	\$ 307.61	\$ 2,518,296	\$ 54.30
Varicella F	Varivax®	00006-4827-00	7,620	\$ 151.45	\$ 1,239,836	11%	\$ 183.00	\$ 1,498,173	\$ 33.90
Meningococcal Conjugate (Groups A, C, W and Y) F	MenQuadfi™	49281-0590-10	6,770	\$ 114.36	\$ 831,791	7%	\$ 171.97	\$ 1,250,828	\$ 61.90
Rotavirus, Live, Oral, Pentavalent F	RotaTeq®	00006-4047-41	8,450	\$ 84.02	\$ 762,747	7%	\$ 98.82	\$ 897,107	\$ 15.90
DTaP-IPV-HIB-HEPB E	Vaxelis™	63361-0243-15	5,000	\$ 103.76	\$ 557,380	5%	\$ 156.70	\$ 841,764	\$ 56.88
Respiratory Syncytial Virus (RSV)	BeyfortusTM	49281-0574-15	1,200	\$ 414.75	\$ 534,711	5%	\$ 556.13	\$ 716,986	\$ 151.90
Respiratory Syncytial Virus (RSV)	BeyfortusTM	49281-0575-15	1,200	\$ 414.75	\$ 534,711	5%	\$ 556.13	\$ 716,986	\$ 151.90
Pneumococcal	VaxneuvanceTM	00006-4329-03	2,720	\$ 175.45	\$ 512,712	4%	\$ 229.20	\$ 669,784	\$ 57.75
DTaP-Hep B-IPV D	Pediarix®	58160-0811-52	5,460	\$ 67.94	\$ 398,532	3%	\$ 103.62	\$ 607,838	\$ 38.33

Top 10 Vaccines - Adult

Vaccine	Brandname/ Tradename	NDC	Dose Quantity	CDC Cost/ Dose	Projected Vaccine Cost	% of Total	Private Sector Cost/ Dose	Projected Private Cost	\$ Savings Per Dose
Covid-19 (Age 12 years and older)	Spikevax™	80777-0110-93	12,830	\$ 78.28	\$ 1,088,885	19%	\$ 141.80	\$ 1,972,456	\$ 68.87
Pneumococcal 20-valentF	Pprevnar 20™	00005-2000-10	3,600	\$ 178.56	\$ 684,291	12%	\$ 274.60	\$ 1,052,343	\$ 102.24
Covid-19 (Age 12 years and older)	Comirnaty®	00069-2432-10	7,880	\$ 69.44	\$ 593,254	10%	\$ 136.75	\$ 1,168,310	\$ 72.98
Zoster Vaccine Recombinant, Adjuvanted	Shingrix®	58160-0823-11	4,250	\$ 124.56	\$ 563,527	10%	\$ 215.51	\$ 975,004	\$ 96.82
HPV-Human Papillomavirus 9 ValentF	Gardasil®9	00006-4121-02	2,110	\$ 191.00	\$ 429,010	7%	\$ 307.61	\$ 690,935	\$ 124.13
Respiratory Syncytial Virus (RSV)	Abrysvo™	00069-2465-10	2,000	\$ 181.28	\$ 385,953	7%	\$ 306.80	\$ 653,190	\$ 133.62
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular PertussisB	Boostrix®	58160-0842-52	12,360	\$ 28.89	\$ 380,054	7%	\$ 48.75	\$ 641,375	\$ 21.14
Influenza F	Fluzone® High-dose TIV	49281-0125-65	4,550	\$ 56.45	\$ 276,834	5%	\$ 75.54	\$ 370,431	\$ 20.57
Influenza F	Afluria®	33332-0025-03	15,892	\$ 15.52	\$ 265,812	5%	\$ 21.60	\$ 369,858	\$ 6.55
Influenza F	Fluzone®	49281-0643-15	15,892	\$ 13.93	\$ 238,494	4%	\$ 19.48	\$ 333,686	\$ 5.99

Alaska Calendar Year 2026 Assessment

Comparison to Prior Period

		Cost Per Dose	Doses	Cost
Total Pediatric	Prior Period Projected	\$ 94.43	140,920	\$ 13,307,497
	Current Period Projected	\$ 96.01	121,838	\$ 11,697,708
	Variance	\$ 1.58	-19,082	\$ (1,609,789)
	% Variance	1.7%	-13.5%	-12.1%
Total Adult	Prior Period Projected	\$ 61.00	94,810	\$ 5,783,462
	Current Period Projected	\$ 61.23	93,420	\$ 5,720,371
	Variance	\$ 0.23	-1,390	\$ (63,092)
	% Variance	0.4%	-1.5%	-1.1%
Pediatric	Prior Period Projected	\$ 111.37	107,190	\$ 11,938,012
	Current Period Projected	\$ 112.73	97,800	\$ 11,024,877
	Variance	\$ 1.36	-9,390	\$ (913,136)
	% Variance	1.2%	-8.8%	-7.6%
Adult	Prior Period Projected	\$ 93.63	31,910	\$ 2,987,616
	Current Period Projected	\$ 95.81	32,550	\$ 3,118,649
	Variance	\$ 2.18	640	\$ 131,033
	% Variance	2.3%	2.0%	4.4%
Pediatric Flu	Prior Period Projected	\$ 17.57	22,330	\$ 392,445
	Current Period Projected	\$ 18.55	20,720	\$ 384,425
	Variance	\$ 0.98	-1,610	\$ (8,020)
	% Variance	5.6%	-7.2%	-2.0%
Adult Flu	Prior Period Projected	\$ 23.03	44,240	\$ 1,019,065
	Current Period Projected	\$ 22.52	39,820	\$ 896,711
	Variance	\$ (0.52)	-4,420	\$ (122,354)
	% Variance	-2.2%	-10.0%	-12.0%
Pediatric COVID-19	Prior Period Projected	\$ 85.71	11,400	\$ 977,040
	Current Period Projected	\$ 86.92	3,318	\$ 288,406
	Variance	\$ 1.22	-8,082	\$ (688,634)
	% Variance	1.4%	-70.9%	-70.5%
Adult COVID-19	Prior Period Projected	\$ 95.22	18,660	\$ 1,776,781
	Current Period Projected	\$ 81.00	21,050	\$ 1,705,011
	Variance	\$ (14.22)	2,390	\$ (71,770)
	% Variance	-14.9%	12.8%	-4.0%

Alaska Calendar Year 2026 Assessment

Summary Statistics

Current Assessment Period											
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Vaccine Waste Allowance	Projected Vaccine Cost
Total Pediatric	121,838	\$ 10,884,482	\$ 15,193,381	\$ 16,328,934	\$ -	2.8%	\$ 309,497	0.0%	\$ -	\$ 503,729	\$ 11,697,708
Total Adult	93,420	\$ 5,334,274	\$ 9,056,948	\$ 9,714,416	\$ -	2.6%	\$ 139,765	0.0%	\$ -	\$ 246,332	\$ 5,720,371
Pediatric	97,800	\$ 10,261,774	\$ 14,306,409	\$ 15,370,285	\$ -	2.8%	\$ 288,347	0.0%	\$ -	\$ 474,755	\$ 11,024,877
Adult	32,550	\$ 2,929,626	\$ 4,962,924	\$ 5,283,137	\$ -	1.9%	\$ 54,727	0.0%	\$ -	\$ 134,296	\$ 3,118,649
Pediatric Flu	20,720	\$ 356,697	\$ 464,272	\$ 500,363	\$ -	3.1%	\$ 11,174	0.0%	\$ -	\$ 16,554	\$ 384,425
Adult Flu	39,820	\$ 832,031	\$ 1,148,962	\$ 1,238,280	\$ -	3.1%	\$ 26,066	0.0%	\$ -	\$ 38,614	\$ 896,711
Pediatric COVID-19	3,318	\$ 266,011	\$ 422,700	\$ 458,286	\$ -	3.8%	\$ 9,975	0.0%	\$ -	\$ 12,419	\$ 288,406
Adult COVID-19	21,050	\$ 1,572,617	\$ 2,945,062	\$ 3,192,999	\$ -	3.8%	\$ 58,973	0.0%	\$ -	\$ 73,422	\$ 1,705,011

Prior Assessment Period											
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Vaccine Waste Allowance	Projected Vaccine Cost
Total Pediatric	140,920	\$ 12,390,884	\$ 17,543,456	\$ 18,840,785	\$ -	2.8%	\$ 343,563	0.0%	\$ -	\$ 573,050	\$ 13,307,497
Total Adult	94,810	\$ 5,416,128	\$ 8,166,024	\$ 8,715,249	\$ -	2.2%	\$ 118,285	0.0%	\$ -	\$ 249,049	\$ 5,783,462
Pediatric	107,190	\$ 11,111,706	\$ 15,721,319	\$ 16,890,413	\$ -	2.8%	\$ 312,230	0.0%	\$ -	\$ 514,077	\$ 11,938,012
Adult	31,910	\$ 2,806,534	\$ 4,514,982	\$ 4,806,293	\$ -	1.9%	\$ 52,428	0.0%	\$ -	\$ 128,654	\$ 2,987,616
Pediatric Flu	22,330	\$ 364,137	\$ 489,458	\$ 527,396	\$ -	3.1%	\$ 11,408	0.0%	\$ -	\$ 16,900	\$ 392,445
Adult Flu	44,240	\$ 945,560	\$ 1,055,456	\$ 1,137,504	\$ -	3.1%	\$ 29,622	0.0%	\$ -	\$ 43,883	\$ 1,019,065
Pediatric COVID-19	11,400	\$ 915,041	\$ 1,332,679	\$ 1,422,976	\$ -	2.2%	\$ 19,926	0.0%	\$ -	\$ 42,073	\$ 977,040
Adult COVID-19	18,660	\$ 1,664,034	\$ 2,595,587	\$ 2,771,452	\$ -	2.2%	\$ 36,235	0.0%	\$ -	\$ 76,512	\$ 1,776,781

	CDC Cost to Private Cost %	Difference Between CDC Cost/ Dose and Private Cost/ Dose	Cost Change Due to Price Change	% Change in Cost/ Dose	Change in Dose Quantity	Cost at Prior Year Dose Quantity	Cost Change Due to Dose Change	% Cost Change Due to Dose Change	Total Cost Change
Total Pediatric	-28.4%	\$ (2,164.18)	\$ 483,122	3.9%	(19,082)	\$ 12,874,006	\$ (1,989,524)	-15.5%	\$ (1,506,402)
Total Adult	-41.1%	\$ (2,312.15)	\$ (1,270,149)	-23.5%	(1,390)	\$ 4,145,979	\$ 1,188,294	28.7%	\$ (81,855)
Pediatric	-28.3%	\$ (1,765.84)	\$ 485,825	4.4%	(9,390)	\$ 11,597,531	\$ (1,335,757)	-11.5%	\$ (849,932)
Adult	-41.0%	\$ (1,996.78)	\$ (33,696)	-1.2%	640	\$ 2,772,838	\$ 156,788	5.7%	\$ 123,092
Pediatric Flu	-23.2%	\$ (82.85)	\$ (3,148)	-0.9%	(1,610)	\$ 360,989	\$ (4,292)	-1.2%	\$ (7,441)
Adult Flu	-27.6%	\$ (104.89)	\$ (945,560)	-100.0%	(4,420)	\$ -	\$ 832,031		\$ (113,529)
Pediatric COVID-19	-37.1%	\$ (315.49)	\$ 446	0.0%	(8,082)	\$ 915,486	\$ (649,475)	-70.9%	\$ (649,029)
Adult COVID-19	-46.6%	\$ (210.48)	\$ (290,893)	-17.5%	2,390	\$ 1,373,141	\$ 199,476	14.5%	\$ (91,417)